Navigation Links
Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases

Niobe Performs with Peerless Safety and Proven Efficacy in all Four

Chambers of the Heart Stereotaxis to Introduce Major New Software Platform for Niobe at Heart

Rhythm 2008

ST. LOUIS, May 1 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS), announced today that approximately 15,000 procedures have been performed using Stereotaxis' Niobe(R) Magnetic Navigation System. The Niobe System has been used to perform procedures in all four chambers of the heart and in every type of cardiac patient, from pediatric to geriatric, with exemplary precision, efficacy and safety. Most notably, major adverse events directly attributable to the use of the Magnetic Navigation System have occurred in fewer than 0.1% of the approximately 15,000 cases, which include over 3,500 complex electrophysiology procedures.

A total of 87 peer-reviewed publications on magnetic navigation have appeared since the inception of Niobe, showing excellent results ranging from 98.6% chronic success for SVT, to 76% chronic success for life-threatening ischemic VT.

"In my career, I have had the opportunity to evaluate a great deal of new technology," said Dr. J. David Burkhardt, Chief Medical Officer of Stereotaxis, and formerly of The Cleveland Clinic Foundation, where he performed more than 300 cases using the Stereotaxis Niobe System, as well as a number of cases with competing technology. "Most devices are designed for a particular procedure. The unique quality of the Stereotaxis system is its ability to perform any interventional electrophysiology procedure in any chamber of the heart. The system also has the ability to navigate those catheters from any approach, not just the standard femoral vein access site. In essence, this is the only new technology that can replace the manual skills of the ablationist for every procedure. For the Interventional Cardiologist or implanters of Cardiac Resynchronization Therapy devices, the ability to control the tip of the wire and navigate it through any blood vessel from any approach is also unique. In addition, I am amazed by the low frequency of major complications. We are continuing to learn about the importance of pressure in complications such as steam pop, perforation and atrial-esophageal fistula. The ability of this system to navigate and ablate without producing dangerous pressures, certainly seems to contribute to its safety record."

"With nearly 100 installations worldwide, we are extremely pleased that the Niobe system has maintained such a remarkable record for safety and efficacy, given the large and diverse group of clinicians using the system," said Bevil Hogg, CEO of Stereotaxis. "As the Niobe's reputation for success and safety continues to spread, we believe that informed patients will begin to self-refer to centers that have the Niobe System when seeking treatment for their complex arrhythmias, and that the Niobe System will enable clinicians to confidently perform cardiac ablations in areas of the heart once thought unreachable or potentially unsafe with manual techniques or alternative technologies."

"We look forward to introducing our new Navigant 3.0 software platform at HRS, the development of which has benefited from the collective experience of hundreds of users of our system over the many thousands of cases done," Mr. Hogg added. "We believe Navigant 3.0 will accelerate adoption of our Niobe system as a new standard of care in the treatment of complex arrhythmias by expanding its automated features and 3D capabilities while greatly simplifying ease of use."

Navigant 3.0, is the next generation user interface software for Niobe, and it will provide users with a significant number of enhanced features and new capabilities ranging from much simplified ease of use, including automated registration of a partner's mapping system as well as faster and more accurate automation with re-targeting to compensate for patient movement, coupled with comprehensive recall of previous catheter locations. Stereotaxis will demonstrate Navigant 3.0 in its Booth #304 at Heart Rhythm 2008 to be held from May 14 to 17 at the Moscone Center in San Francisco. Navigant 3.0 is expected to be commercially available toward the end of 2008 and Stereotaxis believes that, particularly when used in combination with Odyssey, it will significantly advance EP lab productivity and procedural workflow management.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
2. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
3. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
4. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
5. Stereotaxis Receives $20 Million in Additional Loan Commitments
6. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
7. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
8. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
9. A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
10. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
11. Penn research shows transcranial magnetic stimulation effective in treating major depression
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology: